Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Biologics Are Coming, Commissioner McClellan Tells MBC

Executive Summary

Biogen is understood to be drafting a position statement on generic biologics on behalf of the Massachusetts Biotechnology Council

You may also be interested in...



FDA Will Be Given Cost-Effectiveness Role, Acting Commissioner Predicts

Congress is likely to consider expanding FDA's mission to include direct consideration of economic factors in making approval decisions, Acting Commissioner Lester Crawford, PhD, predicted

FDA Will Be Given Cost-Effectiveness Role, Acting Commissioner Predicts

Congress is likely to consider expanding FDA's mission to include direct consideration of economic factors in making approval decisions, Acting Commissioner Lester Crawford, PhD, predicted

BIO Petition Opposes Generic Insulin, HGH; Asks FDA To Open Public Debate

The Biotechnology Industry Organization is asking FDA to initiate a public comment process on generic biologics before it moves forward in creating approval pathways for generic therapeutic proteins

Related Content

UsernamePublicRestriction

Register

PS041315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel